治疗相关的急性髓性白血病的生存结果和预后因素:一项SEER数据库研究,2000-2020年
Utsav Joshi1, Uttam Bhetuwal2, Sumeet K Yadav3
1Department of Hematology, Moffitt Cancer Center, Tampa, FL.
Clinical lymphoma, myeloma & leukemia
|August 2, 2024
概括
在过去十年中,与治疗相关的急性髓性白血病 (tAML) 的存活率有所改善,特别是在老年患者中. 然而,tAML的长期结果仍然很差,这凸显了进一步进步的必要性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 与治疗相关的急性髓性白血病 (tAML) 发病率正在上升,这是由于改善的癌症治疗方法和更长的患者存活率.
- 了解tAML的生存趋势和预后因素对于临床管理至关重要.
研究的目的:
- 在过去20年中,评估与治疗相关的急性髓性白血病 (tAML) 的生存结果趋势.
- 评估社会人口统计学因素与tAML患者的存活率之间的关联.
主要方法:
- 利用监测,流行病学和最终结果 (SEER) 数据库来识别2000年至2020年间诊断的tAML患者.
- 根据年龄组 (18-39,40-59,60-69,>=70岁) 和诊断时期 (2000-2005,2006-2010,2011-2015,2016-2020) 分类患者.
- 采用卡普兰-梅尔和日志等级方法来比较整体存活率 (OS).
主要成果:
- 总生存率 (OS) 根据年龄组有显著差异,年轻患者 (18-39岁) 的生存率高于老年人群 (>=70岁).
- 在整个诊断期内,特别是从2011-2015年开始,观察到1年的OS显著改善.
- 年龄,诊断年份和地理位置被确定为tAML中OS的独立预后标志物.
结论:
- 在过去的十年中,tAML患者的1年生存期显著改善,这表明治疗疗效的进展.
- 尽管短期有所改善,但tAML的长期预后仍然具有挑战性.
- 近年来,老年tAML患者的生存率有所提高,这可能是由于新的治疗选择.
相关概念视频
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:15Assumptions of Survival Analysis
114
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
114
01:24Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
01:20Comparing the Survival Analysis of Two or More Groups
166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K